Updated 2024-25 COVID vaccine cut emergency visits among kids, study suggests

A CDC analysis of electronic health records from more than 98,000 pediatric cases in nine states found the 2024–25 Omicron JN.1–targeted COVID vaccine substantially reduced emergency and urgent care visits among children and adolescents from August 2024 to September 2025: vaccine effectiveness was 76% for ages 9 months–4 years during days 7–179 after vaccination (stable through 299 days) and 56% for ages 5–17 in the 7–179 day window (declining to 45% out to 299 days); hospitalization rates were notably higher in infants 6–11 months than in most adult groups, underscoring potential benefits for the youngest children. The authors cite limitations including possible vaccination misclassification, incomplete prior-infection records and limited power to assess hospitalizations, but conclude the 2024–25 dose provided meaningful additional protection — a finding that contrasts with recent federal rollbacks of vaccine recommendations for healthy pregnant women and children.

Analysis

The CDC's test-negative, case-control analysis of electronic health records covering more than 98,000 pediatric cases across nine states from August 2024 to September 2025 evaluated the 2024–25 Omicron JN.1–targeted COVID-19 vaccine. Researchers measured added protection from the updated dose in children and adolescents many of whom had prior infection or vaccination, providing season-specific real-world effectiveness data.

Vaccine effectiveness (VE) against COVID-associated emergency department and urgent care visits was 76% for children aged 9 months to 4 years during days 7–179 post-vaccination and remained stable through 299 days; for ages 5–17 VE was 56% at 7–179 days, declining to 45% by 7–299 days. The report also notes that hospitalization rates in infants 6–11 months were higher than all adult age groups except those 65+, underscoring potential benefit in the youngest cohorts.

Authors cite limitations including possible vaccination misclassification, incomplete prior-infection records, and limited power to assess hospitalizations due to fewer severe pediatric cases. The findings provide evidence of meaningful additional protection from the 2024–25 dose even as federal recommendations for healthy pregnant women and children were removed, creating a policy-demand gap investors should monitor.

Key Decisions for Investors

• Monitor pediatric vaccine uptake, ED/UC and infant hospitalization trends and subsequent VE/hospitalization analyses as primary demand indicators for pediatric COVID products
• Reassess exposure to vaccine manufacturers, distributors and pediatric-adjacent biotech where sustained pediatric uptake would support revenues, while keeping positions hedged given policy rollback risk
• Track HHS and CDC guidance and reimbursement signals closely because federal recommendation changes (noted removal for healthy pregnant women and children) can materially alter market size and payer coverage
• For healthcare services and insurers, model potential reductions in pediatric ED/UC volumes from higher VE but stress-test for documentation/misclassification risk and regional variability in uptake